In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models

Nuclear Medicine and Biology

Volumn 40, Issue 6, 2013, Pages 823-830

  Meckel, Marian ^a   Fellner, Marco ^a   Thieme, Natalie ^b   Bergmann, Ralf ^b   Kubicek, Vojteck ^c   Rösch, Frank ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

177Lu; 68Ga; Bisphosphonates; Bone metastases; DOTA; PET

Indexed keywords

[4 [[(BIS PHOSPHONOMETHYL) CARBAMOYL]METHYL] 7,10 BIS (CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL] ACETIC ACID GALLIUM GA 68; [4[[(BIS PHOSPHONOPROPYL) CARBOMOYL]METHYL] 7,10 BIS (CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL] ACETIC ACID GALLIUM GA 68; AMMONIUM ACETATE; BUFFER; CATION EXCHANGE RESIN; FLUORINE 18; MEDRONATE TECHNETIUM TC 99M; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TETRAETHYL 10 [[(2,2 BIS PHOSPHONOETHYL)HYDROXYPHOSPHORYL]]METHYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIACETIC ACID GALLIUM GA 68; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; EX VIVO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTUM YIELD; RAT; STRUCTURE ANALYSIS;

EID: 84880991709     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.04.012     Document Type: Article

References (14)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer Statistics 2001 CA. Cancer J Clin 2001, 51:15-36.
2. Rubens R.D. Bone metastases - the clinical problem. Eur J Cancer 1998, 34:210-213.
3. Zettinig G., Dudczak R., Leitha T. Nuklearmedizinische diagnostik der osteomyelitis. J Mineralstoffw 2003, 10:20-23.
4. Harmer C.L., Burns J.E., Sams A., Spittle M. The value of fluorine-18 for scanning bone tumours. Clin Radiol 1969, 20:204-212.
5. Papapoulos S.E. Bisphosphonates: how do they work?. Best Pract Res Cl En 2008, 22:831-847.
6. Kubíček V., Rudovský J., Kotek J., Hermann P., Vander Elst L., Muller R.N., et al. A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J Am Chem Soc 2005, 127:16477-16485.
7. 68Ga-bisphosphonates: first human study. Nucl Med Mol Imag 2010, 37:834.
8. Vitha T., Kubíček V., Hermann P., Kolar Z.I., Wolterbeek H.Th., Peters J.A., et al. Complexes of DOTA-bisphosphonate conjugates: probes for determination of adsorption capacity and affinity constants of hydroxyapatite. Langmuir 2008, 24:1952-1958.
9. 68Ga for medical application. J Nucl Med 2007, 48:1741-1748.
10. 68Ga-DOTATOC. Nuc Med Biol 2008, 35:721-724.
11. 68Ga-bisphosphonates for imaging bone diseases. J Nucl Med 2010, 51:563.
12. 233U in different bones of one-year-old rats: macrodistribution and macrodosimetry. Human Toxicol 1984, 3:469-483.
13. Chollet C., Bergmann R., Pietzsch J., Beck-Sickinger A.G. Design, evaluation and comparison of ghrelin receptor agonists and inverse agonists as suitable radiotracers for PET imaging. Bioconj. Chem 2012, 23:771-784.
14. Vitha T., Kubíček V., Hermann P., Elst L.V., Muller R.N., Kolar Z.I., et al. Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: Bone-seeking agents for imaging and therapy. J Med Chem 2008, 51:677-683.